---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-003376"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2024-01-09T23:59:59+00:00"
generated_at: "2026-06-07T01:41:53.701194+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nuvalent reports $719.9M cash; launches 'OnTarget 2026' plan targeting first approval in 2026

## Summary
- Cash, cash equivalents and marketable securities of $719.9M as of Dec 31, 2023 (unaudited); expected to fund operations into 2027.
- OnTarget 2026 plan aims for first potential approved product in 2026, with pivotal data from at least one lead program in 2025.
- 2024 milestones: advance Phase 2 ARROS-1 (NVL-520) and initiate Phase 2 ALKOVE-1 (NVL-655), launch front-line ALK strategy, start Phase 1 for HER2 program.
- Interim data from ARROS-1 and ALKOVE-1 expected at medical meetings in 2024.
- Company to present at J.P. Morgan Healthcare Conference on Jan 9, 2024.

## SEC filing metadata
- accession: 0000950170-24-003376
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2024-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000095017024003376/0000950170-24-003376-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000095017024003376/nuvl-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-003376
- JSON: https://secwatch.observer/filing/0000950170-24-003376.json
- Plain text: https://secwatch.observer/filing/0000950170-24-003376.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.